First Time Loading...

Elevation Oncology Inc
NASDAQ:ELEV

Watchlist Manager
Elevation Oncology Inc Logo
Elevation Oncology Inc
NASDAQ:ELEV
Watchlist
Price: 4.07 USD -1.69%
Updated: Apr 18, 2024

Intrinsic Value

ELEV's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Elevation Oncology, Inc. operates as a precision oncology company. [ Read More ]

The intrinsic value of one ELEV stock under the Base Case scenario is 1.09 USD. Compared to the current market price of 4.07 USD, Elevation Oncology Inc is Overvalued by 73%.

Key Points:
ELEV Intrinsic Value
Base Case
1.09 USD
Overvaluation 73%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Elevation Oncology Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ELEV stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Elevation Oncology Inc

Provide an overview of the primary business activities
of Elevation Oncology Inc.

What unique competitive advantages
does Elevation Oncology Inc hold over its rivals?

What risks and challenges
does Elevation Oncology Inc face in the near future?

Has there been any significant insider trading activity
in Elevation Oncology Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Elevation Oncology Inc.

Provide P/S
for Elevation Oncology Inc.

Provide P/E
for Elevation Oncology Inc.

Provide P/OCF
for Elevation Oncology Inc.

Provide P/FCFE
for Elevation Oncology Inc.

Provide P/B
for Elevation Oncology Inc.

Provide EV/S
for Elevation Oncology Inc.

Provide EV/GP
for Elevation Oncology Inc.

Provide EV/EBITDA
for Elevation Oncology Inc.

Provide EV/EBIT
for Elevation Oncology Inc.

Provide EV/OCF
for Elevation Oncology Inc.

Provide EV/FCFF
for Elevation Oncology Inc.

Provide EV/IC
for Elevation Oncology Inc.

Show me price targets
for Elevation Oncology Inc made by professional analysts.

What are the Revenue projections
for Elevation Oncology Inc?

How accurate were the past Revenue estimates
for Elevation Oncology Inc?

What are the Net Income projections
for Elevation Oncology Inc?

How accurate were the past Net Income estimates
for Elevation Oncology Inc?

What are the EPS projections
for Elevation Oncology Inc?

How accurate were the past EPS estimates
for Elevation Oncology Inc?

What are the EBIT projections
for Elevation Oncology Inc?

How accurate were the past EBIT estimates
for Elevation Oncology Inc?

Compare the revenue forecasts
for Elevation Oncology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Elevation Oncology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Elevation Oncology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Elevation Oncology Inc compared to its peers.

Compare the P/E ratios
of Elevation Oncology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Elevation Oncology Inc with its peers.

Analyze the financial leverage
of Elevation Oncology Inc compared to its main competitors.

Show all profitability ratios
for Elevation Oncology Inc.

Provide ROE
for Elevation Oncology Inc.

Provide ROA
for Elevation Oncology Inc.

Provide ROIC
for Elevation Oncology Inc.

Provide ROCE
for Elevation Oncology Inc.

Provide Gross Margin
for Elevation Oncology Inc.

Provide Operating Margin
for Elevation Oncology Inc.

Provide Net Margin
for Elevation Oncology Inc.

Provide FCF Margin
for Elevation Oncology Inc.

Show all solvency ratios
for Elevation Oncology Inc.

Provide D/E Ratio
for Elevation Oncology Inc.

Provide D/A Ratio
for Elevation Oncology Inc.

Provide Interest Coverage Ratio
for Elevation Oncology Inc.

Provide Altman Z-Score Ratio
for Elevation Oncology Inc.

Provide Quick Ratio
for Elevation Oncology Inc.

Provide Current Ratio
for Elevation Oncology Inc.

Provide Cash Ratio
for Elevation Oncology Inc.

What is the historical Revenue growth
over the last 5 years for Elevation Oncology Inc?

What is the historical Net Income growth
over the last 5 years for Elevation Oncology Inc?

What is the current Free Cash Flow
of Elevation Oncology Inc?

Financials

Balance Sheet Decomposition
Elevation Oncology Inc

Current Assets 88m
Cash & Short-Term Investments 83.1m
Other Current Assets 4.9m
Non-Current Assets 1.1m
PP&E 59k
Other Non-Current Assets 1.1m
Current Liabilities 4.1m
Accounts Payable 507k
Accrued Liabilities 3.6m
Non-Current Liabilities 30.1m
Long-Term Debt 30.1m
Efficiency

Earnings Waterfall
Elevation Oncology Inc

Revenue
0 USD
Operating Expenses
-40.3m USD
Operating Income
-40.3m USD
Other Expenses
-5.4m USD
Net Income
-45.7m USD

Free Cash Flow Analysis
Elevation Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ELEV Profitability Score
Profitability Due Diligence

Elevation Oncology Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Elevation Oncology Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ELEV Solvency Score
Solvency Due Diligence

Elevation Oncology Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
47/100
Solvency
Score

Elevation Oncology Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ELEV Price Targets Summary
Elevation Oncology Inc

Wall Street analysts forecast ELEV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ELEV is 7.91 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
49% Upside
Average
Price Target
7.91 USD
94% Upside
Highest
Price Target
10.5 USD
158% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ELEV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ELEV Price
Elevation Oncology Inc

1M 1M
-7%
6M 6M
+531%
1Y 1Y
+113%
3Y 3Y
-64%
5Y 5Y
-64%
10Y 10Y
-64%
Annual Price Range
4.07
52w Low
0.38
52w High
5.17
Price Metrics
Average Annual Return -66.03%
Standard Deviation of Annual Returns 25.77%
Max Drawdown -98%
Shares Statistics
Market Capitalization 198m USD
Shares Outstanding 48 651 100
Percentage of Shares Shorted 11.44%

ELEV Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Elevation Oncology Inc Logo
Elevation Oncology Inc

Country

United States of America

Industry

Biotechnology

Market Cap

198m USD

Dividend Yield

0%

Description

Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.

Contact

NEW YORK
New York City
888 Seventh Ave, 12Th Floor
+12126516380.0
https://elevationoncology.com/

IPO

2021-06-25

Employees

35

Officers

Chief Scientific Officer
Dr. David Dornan Ph.D.
Chief Medical Officer
Ms. Valerie Malyvanh Jansen M.D., Ph.D.
CEO, President & Director
Mr. Joseph J. Ferra Jr.
CFO & Secretary
Ms. Tammy Furlong CPA, P.M.P.
Head of Tech Ops
Mr. Ryan Bloomer
Senior Director of Corporate Communications & Investor Relations
Candice Masse
Show More
Vice President of Legal Affairs
Mr. Robert C. Yang
Show Less

See Also

Discover More
What is the Intrinsic Value of one ELEV stock?

The intrinsic value of one ELEV stock under the Base Case scenario is 1.09 USD.

Is ELEV stock undervalued or overvalued?

Compared to the current market price of 4.07 USD, Elevation Oncology Inc is Overvalued by 73%.